Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation.

Cannarile, Michael A; Gomes, Bruno; Canamero, Marta; Reis, Bernhard; Byrd, Allyson; Charo, Jehad; Yadav, Mahesh; Karanikas, Vaios

Cannarile, Michael A; Gomes, Bruno; Canamero, Marta; Reis, Bernhard; Byrd, Allyson; Charo, Jehad; Yadav, Mahesh; Karanikas, Vaios.

Afiliación

Cannarile MA; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.
Gomes B; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.
Canamero M; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.
Reis B; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.
Byrd A; Genentech, South San Francisco, California.
Charo J; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland.
Yadav M; Genentech, South San Francisco, California.
Karanikas V; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland. vaios.karanikas@roche.com.

Clin Cancer Res ; 27(15): 4147-4159, 2021 08 01.

Article en En | MEDLINE | ID: mdl-33766813

Asunto(s)

Biomarcadores de Tumor; Neoplasias/etiología; Neoplasias/inmunología; Neoplasias/patología; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google